Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

The University of Alabama at Birmingham

Status: Enrolling

Conditions: Hemophagocytic Lymphohistiocytoses; Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT05898477

IRB-300010383

Details and patient eligibility

About

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Full description

Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma

Enrollment: 2,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with lymphoma that are fulfilling at least one of the following:

A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)

Exclusion criteria

• Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
• Patients with incomplete treatment and response documentation

Trial design

2,000 participants in 1 patient group

Hemophagocytic lymphohistiocytosis (HLH) Patients